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CObjective: Exercise therapy in heart failure (HF) patients is considered
safe and has demonstrated modest reduction in hospitalization rates
and death in recent trials. Previous cost-effectiveness analysis de-
scribed favorable results considering long-term supervised exercise in-
tervention and significant effectiveness of exercise therapy; however,
these evidences are now no longer supported. To evaluate the cost-
effectiveness of supervised exercise therapy in HF patients under the
perspective of the Brazilian Public Healthcare System. Methods: We
developed a Markov model to evaluate the incremental cost-effective-
ness ratio of supervised exercise therapy compared to standard treat-
ment in patients with New York Heart Association HF class II and III.
Effectiveness was evaluated in quality-adjusted life years in a 10-year
time horizon. We searched PUBMED for published clinical trials to es-
timate effectiveness, mortality, hospitalization, and utilities data.
Treatment costs were obtained from published cohort updated to 2008
values. Exercise therapy intervention costs were obtained from a reha- O
hav
r Hea
gre, R
al So
oi:10.1016/j.jval.2011.05.006ilitation center. Model robustness was assessed through Monte Carlo
imulation and sensitivity analysis. Cost were expressed as interna-
ional dollars, applying the purchasing-power-parity conversion rate.
esults: Exercise therapy showed small reduction in hospitalization
nd mortality at a low cost, an incremental cost-effectiveness ratio of
nt$26,462/quality-adjusted life year. Results were more sensitive to
xercise therapy costs, standard treatment total costs, exercise therapy
ffectiveness, andmedications costs. Considering awillingness-to-pay
f Int$27,500, 55% of the trials fell below this value in the Monte Carlo
imulation. Conclusions: In a Brazilian scenario, exercise therapy
hows reasonable cost-effectiveness ratio, despite current evidence of
imited benefit of this intervention.
eywords: costs, health economics, heart failure, physical therapy.
opyright © 2011, International Society for Pharmacoeconomics and
utcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Heart failure (HF) is a common health care problem worldwide,
with elevated costs associated to its treatment [1]. During the past
20 years several effective therapies have changedHFmanagement
and clinical outcomes and these have been formally evaluated
through economic analyses [2-4]. The decrease in HF mortality
was followed by an increase in its prevalence, with direct effect on
health care budgets resulting from the rising number of hospital-
izations and therapeutic procedures [5].
HF is a complex syndrome characterized by reduced exercise
tolerance and the involvement of multiple physiopathologic
mechanisms [6]. In the past patients were often advised to limit
their efforts in daily activities; however, several studies suggest
that exercise training may reduce mortality and morbidity in HF
patients [7,8]. These studies also demonstrated that exercise train-
ing could be performed safely in appropriately evaluated cases of
patients who present in clinically compensated New York Heart
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ublished by Elsevier Inc.Association (NYHA) functional class II and III, as endorsed by cur-
rent guidelines [9,10].
For health care managers, the decision to incorporate exercise
therapy in treatment of patients with HF should be based in sev-
eral perspectives, including cost-effectiveness studies of the inter-
vention. In 2001, Georgiou et al. [11] published a cost-effectiveness
analysis of supervised exercise intervention in HF patients show-
ing a very favorable cost-effectiveness ratio of $1773 per life-year
saved, considering a 14-month period of supervised exercise in-
tervention in a time horizon of 10 years applied to a North-Amer-
ican setting.
Recently a multicenter randomized controlled trial of 2331 HF
outpatients [12] described an exercise-based intervention being
compared with standard treatment. After 2.5 years of follow-up,
including a short training period in a facility followed by home-
based exercise sessions, a benefit was observed only after adjust-
ment for other prognostic predictors of the primary endpoint. The
authors concluded that exercise training is a safe intervention as-
sociatedwith amodest reduction in hospitalization andmortality,
e no conflicts of interest with regard to the content of this
lth Technology Assessment, Hospital de Clínicas de Porto Alegre,
S, Brazil.
ciety for Pharmacoeconomics and Outcomes Research (ISPOR).
S101V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) S 1 0 0 – S 1 0 7far from the assumed estimations in previous cost-effectiveness
analysis [12].
In this studywe evaluated the economic impact of a supervised
exercise intervention in a hypothetic stable outpatient HF cohort,
considering current evidence of effectiveness and costs, offering
health care professionals an updated assessment on the role of
exercise in the management of HF.
Methods
Target population
The target population was composed of 60-year old patients at
baseline, with clinically stable NYHA class II or III HF, intended to
reproduce the population in exercise interventions studies in HF.
Decision model structure
We developed a model based on two competing strategies: 1)
standard HF care; and 2) standard HF care plus an exercise-
based intervention [13]. We constructed our decision tree model
with Markov transitional states using TreeAge Pro 2009 Suite
software (release 1.0.1, TreeAge Software Inc., Williamstown,
MA), tracking a hypothetical cohort of HF patients over time
receiving one of the strategies. During each 1-year cycle, pa-
tients could remain alive or die; patients alive could also remain
stable or be hospitalized. After having been hospitalized, these
patients could die or remain alive, with a lower survival rate,
simulating the natural history of HF. In the intervention arm we
assumed that exercise could reduce mortality and hospitaliza-
Fig. 1 – Schematic represetion rates, according to expected rates of effectiveness. Wecomputed all-cause mortality in our model, considering evi-
dence of exercise intervention studies. A schematic representa-
tion of our decision tree is shown in Figure 1.
The discount rate for both cost and effectiveness was 5% per
year. We used the public third-party payer perspective and a 10-
year time horizon.
Survival data
Survival rates were based in data from a specialized HF outpa-
tient clinic from a university hospital in Brazil whose patients’
characteristics are similar to the exercise intervention studies’
populations. This cohort was composed of 318 patients (68%
men), with a median age of 61 years (interquartile range 50–71
years). Thirty-seven percent of patients had ischemic heart dis-
ease as the HF etiology; 87%were currently taking beta blockers,
and 91% were taking angiotensin converting enzyme inhibitors.
The prevalence of diabetes mellitus in this cohort was 30%, 41%
of these patients had hypertension, and 11% were tobacco us-
ers. The annual rate of hospital admission in this cohort was
16%, and patients who had been hospitalized had a diminished
survival rate compared with those who had not been hospital-
ized [14].
Median follow-up of this cohort was 75 months (95% confi-
dence interval [CI] 68–81). To project survival during the 10-year
time horizon, we built a survival curve (Fig. 2) using a Weilbull
function. Two different curves were built based on hospitalization
status. The final equations for the survival functions were
Exp(((0.0004*(_stage)^1.0715)) in nonhospitalized patients and
on of the decision model.ntatiExp(((0.00018*(_stage)^1.3627)) in hospitalized patients.
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To estimate quality-adjusted life years (QALYs), we assumed a
utility index of 0.80 for HF (95% CI 0.78–0.82), using recommended
values proposed by Göhler et al. [15] in their decision-analytic
odel, which was weighted by NYHA classes from actual preva-
ence on the Hospital de Clinicas de Porto Alegre cohort (66% and
3% of NYHA class II and III, respectively). We used a discount rate
f 5% (range 3%–7%).
Exercise therapy intervention
The model assumed a supervised exercise therapy session oc-
curring in a facility center, with direct supervision of a qualified
exercise training professional (eg, a physiotherapist). These ses-
sions consist of an initial warm-up, followed by 15 to 30minutes
of aerobic training on a treadmill or performing stationary cy-
cling in individually prescribed program. All patients should be
monitored during the exercise session and each physiothera-
pist could supervise up to four patients each session. In initial
phases of rehabilitation (until 12 weeks), every patient in the
intervention group should participate in at least three weekly
1-hour supervised group-based exercise sessions.
After 36 sessions we determined that patients should return
once a week to the rehabilitation center for additional supervised
sessions during a 9-month period, totaling 72 sessions per year in
the first intervention stage. In subsequent stages we considered a
maintenance program of 50 yearly sessions (weekly supervised
sessions).
Intervention effectiveness
We performed a literature search in PUBMED using “Heart Fail-
ure” and “Exercise Therapy” MeSH terms, selecting randomized
controlled trials published from 1980 to 2009. We included trials
with the following characteristics: 1) randomized parallel group
controlled trials; 2) exercise programs during at least 8 weeks or
more initially based in facility centers; and 3) clinically relevant
endpoints (death and/or hospitalization) described in the re-
sults. Initial search identified 169 articles that were subse-
Fig. 2 – Undiscounted survival curve projections for
standard treatment and exercise therapy plus standard
treatment, compared with actual survival curve of heart
failure (HF) patients.quently scrutinized and those that fulfilled inclusion criteriawere included, as described in the Consort statement (Fig. 3).
Thirteen trials met the eligibility criteria, resulting in a total of
3458 patients being included: 1746 in the exercise group and
1712 in the control group, as shown in Table 1 [7,12,16–26].
When one arm of a study contained no events, we added 0.5 to
each cell to allow effect size calculation. Combined events
(death or hospitalization) showed a pooled risk ratio of 0.878
(95% CI 0.805–0.957) using the Mantel Haenszel fixed-effects
model. Pooled risk reduction for mortality was 0.957 (95% CI
0.865–1.058) and for hospitalization was 0.90 (95% CI 0.831–
0.973).
HF treatment costs
Annual HF treatment costs in the Public Healthcare System
(PHS) were extracted from a Brazilian cohort described by
Araujo et al. [27]. These authors described treatment costs cat-
egorized in outpatients and hospital costs, in 2002 values. We
updated published values to 2008 costs according to the official
Brazilian inflation index [28]. Hospital costs were adapted from
our university hospital billing system, which includes in stan-
dard admission payments some high-complexity diagnostic
procedures, including special drugs and devices. For outpatient
cost estimates for stable conditions we included drug costs,
complementary exams, and ambulatory costs (Table 2). All
costs are expressed in international dollars (Int$), using the pur-
chasing power parity conversion rate. According to a 2008 re-
port of the World Bank regarding conversion rates [29], Int$1 
R$1.357. We used an annual discount rate of 5% in all described
costs, expressed in internation dollars.
Intervention costs (Supervised Exercise)
In Brazil outpatient cardiac rehabilitation procedures are not
reimbursed by the PHS. To establish yearly intervention costs
we used data from a rehabilitation center in a private facility of
an insurance plan, located in the Brazilian state of Santa Ca-
tarina.
Salaries of fitness center personnel accounted for 47% of the
total annual cost of rehabilitation. Maintenance costs (including
rental costs, licenses, and repairs) and equipment costs (e.g.,
cycle ergometers and pulse oximeters) accounted for 33% and
20%, respectively. This structure is able to provide 2000 annual
Fig. 3 – Flow diagram of study selection for exercise
effectiveness.
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Int$66,633, resulting in a single session cost of Int$8.33 per pa-
tient. The proposed cost of each session is similar to the esti-
mated costs per session used by a previously published model
Table 1 – Studies meeting inclusion criteria to estimate exe
Author, year (ref) Sample size
(exercise controls)
Austin, 2005 [16] Exercise: 86
Controls: 98
Belardinelli, 1999 [7] Exercise: 50
Controls: 49
Gianuzzi, 2003 [17] Exercise: 45
Controls: 45
Jolly, 2009 [18] Exercise: 84
Controls: 85
Jonsdottir, 2006 [19] Exercise: 21
Controls: 22
Kiilavuori, 2000 [20] Exercise: 12
Controls: 15
Kulcu, 2007 [21] Exercise: 27
Controls: 26
Hambrecht, 2000 [22] Exercise: 35
Controls: 34
McKelvie, 2002 [23] Exercise: 90
Controls: 91
Nilsson, 2008 [24] Exercise: 40
Controls: 40
O’ Connor, 2009 [13] Exercise: 1159
Controls: 1172
Wielenga, 2000 [25] Exercise: 41
Controls: 39
Willenheimer, 1998 [26] Exercise: 22
Controls: 30
Total Exercise: 1712
Controls: 1746
Table 2 – Model variables, values, and sources.
Variable
Median age of cohort (y)
Annual risk of hospitalization (%)
Exercise variables
Annual hospitalization risk reduction (%)
Annual mortality risk reduction (%)
Costs
Annual exercise intervention costs in the first year (Int$)
Annual exercise intervention cost in 2- to 10-y interval (Int$)
Total annual conventional heart failure treatment costs (Int$)
Annual hospitalization costs (Int$)
Annual ambulatory costs (Int$)
Annual complementary exams costs (Int$)
Annual medication costs (Int$)
Total annual exercise-group heart failure treatment costs
(conventional heart failure treatment cost plus exercise
intervention costs) (Int$)
Utilities
Heart failure patient utility (New York Heart Association
Class II-III)
Discount rate (%)[11], which would cost Int$7.14 in the Brazilian scenario. Values
used in the model are lower than reimbursement values in Bra-
zil (Int$17.65 in the first 12-week program and Int$5.88 in the
maintenance program).
e effectiveness.
Events (exercise, controls)
Combined Deaths Hospitalization
13 5 9
23 4 19
14 9 5
34 20 14
2 0 2
2 1 1
23 7 16
25 5 20
9 2 7
13 2 11
0 0 0
1 0 1
0 0 0
2 1 2
5 3 2
4 2 2
11 11 0
10 10 0
2 2 0
1 1 0
918 189 729
958 198 760
2 1 1
4 4 1
0 0 0
3 0 3
999 229 771
1082 248 834
Base Sensitivity
analysis variation
Source
60 50–70 15
16 10–22 15
0.90 0.831–0.973 Meta-analysis
0.957 0.865–1.058 Meta-analysis
75 187–562 Health care insurance
plan, primary data
00 50–150 Health care insurance
plan, Primary data
52 1,876–5,628 17
98 899–2,697 17
54 27–81 17
63 182–545 17
38 769–2,306 17
87 2,093–6,280 Estimated
0.80 0.78–0.82 16rcis3
1
37
17
3
15
415 3–7 Estimated
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We performed one-way sensitivity analysis in all model parame-
ters described in Table 2. Model effectiveness variables (mortality
and hospitalization reduction with exercise) were varied between
the boundaries of meta-analysis confidence intervals. Costs were
varied 50% of their original values; utilities varied according to
previously described values. Discount varied between 3% and 7%.
Two-way sensitivity analysis was performed in the most impor-
tant model variables.
Model robustness was tested in aMonte Carlo simulation, with
a generation of 1000 trials and variation in the range described
above. Gamma distribution was chosen for cost variables, lognor-
mal distribution for effectiveness, and beta distribution for utility
variables.
Results
The model predicted a mean survival of 5.58 years in the exercise
group and 5.45 years in the control group.When adjusted for qual-
ity of life, we found a mean survival of 4.46 and 4.36 QALYs, re-
spectively, as shown in Table 3. The exercise intervention in-
creased 0.13 life-years and 0.10 QALYs. The total costs in the
intervention group was Int$15,331 and Int$12,720 in the standard
care group. The incremental cost-effectiveness ratio (ICER) was
Int$21,169 per life-year and Int$26,462 per QALY.Monte Carlo sim-
ulation with 1000 trials is represented in Figure 4.
Results from one-way sensitivity analyses are summarized
in Table 4, and our evaluation was adequate to most one-way
analyses. At the lowest values of established intervals for vari-
ables related to HF standard costs of treatment—such as ambu-
latory costs, complementary exam costs, hospitalization costs,
and drugs costs—there was small influence on the ICERs. Utili-
Fig. 4 – Monte Carlo 1000 trials scatter plot. The number of
points below wiliness-to-pay threshold line are 55.2%
(Int$27,500/quality-adjusted life year—three times Brazil’s
Table 3 – Model predicted cost, effectiveness, and cost-effe
Total cost (Int$)
Conventional treatment 12,720
Conventional treatment  Exercise therapy 15,331
Int$, international dollars; LYS, life year saved; QALY, quality-adjust
* All values are discounted.gross domestic product per capita).ties and discount rates variations also produce discrete modifi-
cations on the ICERs, varying between Int$25,816 and Int$27,140
and Int$25,155 and Int$27,832, respectively. More pronounced
effect occurred when varying probability of hospitalization,
with an ICER of Int$24,499 at a 22% annual rate and of Int$30,350
at a 10% annual hospitalization rate.
Three variables had a more expressive effect on the base
case estimates: exercise intervention costs, estimatedmortality
reduction, and estimated hospitalization reduction with reha-
bilitation program. When the relative risk (RR) for hospitaliza-
tion with exercise was 0.83, the ICER would be Int$20,856; with a
RR of 0.97, the ICER increased to Int$36,245. Regarding exercise
costs, a cost of Int$217 per year of supervised exercise produces
an ICER of Int$13,501, and a cost of Int$899 per year increased
the ICER to Int$52,056 (Table 4).
The variable with greater impact on the ICER in the sensitivity
analysis was mortality reduction with exercise: a RR of 0.86 in-
creased 0.24 in total QALY, resulting in an ICER of Int$12,738/
QALY; a RR of 0.96 yielded 0.09 additional QALY and an ICER of
Int$28,141/QALY. Finally, considering no effect onmortality, exer-
cise intervention results in additional 0.04 QALY and an ICER of
Int$66,576/QALY.
Two-way sensitivity analysis altering hospitalization reduc-
tion effect and exercise cost is illustrated in Figure 5. Assuming a
mortality RR of 0.96 with exercise and a willingness-to-pay of
Int$27,495, the exercise intervention should cost below Int$440
yearly to become cost-effective, assuming a RR of 0.90 in hospital-
ization with exercise.
In the Monte Carlo simulation, we established a threshold of
three times the Brazilian gross domestic product, which repre-
sents Int$27,495 (R$37,311) in 2008 and evaluated how many sim-
ulations fell below this value. As shown in Figure 6, 55% of trials
were below this value. In 34% of trials exercise was more costly
ness of competing strategies.
Effectiveness Incremental
cost-effectiveness
ean life years Mean QALYs Int$/LYS Int$/QALY
5.45* 4.36* – –
5.58* 4.46* 21,169 26,461
year.
Table 4 – One-way sensitivity analysis.
Variables Lower ICER
(Int$/QALY)
Higher ICER
(Int$/QALY)
Mortality reduction with exercise 12,738 Dominated
Hospitalization reduction with
exercise
20,856 36,245
Exercise intervention costs 13,501 52,056
Annual rate of hospitalization 24,499 30,350
Utility of heart failure 25,816 27,140
Discount rate 25,155 27,832
Ambulatory costs 26,430 26,493
Hospitalization costs 25,945 26,977
Complementary exam costs 26,251 26,672
Medication costs 25,571 27,353
Note: Range values are those presented in Table 2.
ICER, international cost-effectiveness ratio; Int$, international dol-ctive
M
ed lifelars; QALY, quality-adjusted life year.
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S105V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) S 1 0 0 – S 1 0 7and above the wiliness-to-pay and in 10.8% the exercise interven-
tion was inferior (dominated).
Discussion
The results of this model show that exercise therapy in HF pa-
tients has a modest but favorable incremental cost-effective-
ness ratio of Int$26,462 per QALY and Int$21,169 per life-year in
a Brazilian PHS scenario. The results were consistent consider-
ing sensitivity analyses performed and assumptions described.
Our results show that this intervention has a reasonable cost-
effectiveness ratio when compared to other incoming therapies,
such as implantable cardioverter defibrillator devices [30], but
closer to proposed willingness-to-pay for Brazil, as demon-
strated in the acceptability curve. The ICER of this intervention
is also higher than the estimated Brazilian hemodialysis cost
per life-year gained (US$10,065) [31].
During the past three decades the exercise training approach
oncerning HF patients moved from absolute restraint to enthu-
iastically prescribed, based on a growing body of evidence sug-
esting physiologic and clinical benefit from exercise. Random-
zed controlled trials showed significant reductions in the
omposite endpoint of hospitalization and mortality in HF pa-
ients submitted to supervised sessions of exercise interven-
ions, reaching almost 50% in one report [7], and averaging a
5% reduction in mortality and 28% in hospitalization rates in a
eta-analysis published in 2004 [8]. Nonetheless, a recently
ublished trial failed to prove superiority of an exercise therapy
ntervention in a multicenter-based strategy [12]. The HF-Ac-
ion trial [12] was designed to test the hypothesis that exercise
raining prescribed to HF patients would reduce mortality, and
lthough overall intention-to-treat results were of small mag-
itude, protocol-driven results and those adjusted for prognos-
ic variables indeed suggest some benefit on mortality beyond
eduction of hospitalization and improvement on quality of life,
unctional capacity, and other markers of well-being [32,33].
The true effect of exercise on mortality in this population is
matter of debate, although exercise is still considered a key
spect in the management of HF [9,34]. Our model was sensitive
o this parameter; assuming even a small effect of 4% reduction
n mortality, modest reduction of combined risk of death or
F-related hospitalization, exercise would still have a favorable
ost-effectiveness ratio. Unfortunately we do not have large
Fig. 5 – Three-way sensitivity analysis considering
exercise costs (Int$) and hospitalization risk reduction,
assuming mortality risk reduction with exercise = 0.96 and
a willingness-to-pay of Int$ 27,500.razilian studies describing the actual result of such interven-tions. There are several short-term randomized studies evalu-
ating the effect of exercise among Brazilian HF patients, mostly
limited to physiologic parameters, functional class, or quality of
life [35,36]. We could not identify studies that have evaluated
hard clinical endpoints such as death or hospitalization. Indi-
rect evidence from these studies; however, support the concept
that the results obtained locally are similar to the ones de-
scribed by other international research groups [35,36]. Based on
these assumptions we believe our findings could be a reason-
able estimate of the cost-effectiveness ratio for the Brazilian
PHS scenario, although the effect of the health care system itself
and cultural and socioeconomic characteristics on the main re-
sult might be unpredictable.
In another published cost-effectiveness analysis [11], the im-
pressive absolute reduction of 19% fewer hospitalizations in the
exercise group compared to standard treatment group and ad-
ditional survival of 1.82 years was the determinant factor in
effectiveness estimation, with a cost-effectiveness ratio of
$1773 per life-year saved. In our model, we considered a less
pronounced increase in survival (0.13 years) produced by exer-
cise intervention, reflecting a more realistic ICER taking into
account current data. Prospective economic evaluation from
HF-Action [33] demonstrated that along the trial the exercise
raining program was of little systematic benefit in terms of
verall resource use, but individual data indicate that most es-
imates were consistent with a decrease in costs (89.9%) and an
ncrease in QALYs (76.5%), and that most of the bootstrap rep-
ications were either associated with cost-saving result or with
CER below $50,000 per QALY.
Usual exercise intervention in HF requires at least 12 weeks
f training, because during a period of this length patients can
eceive adequate care and perceive functional improvement,
ncreasing adherence to the intervention. In our model, we de-
ermined that the 36 sessions should be supplemented with
dditional weekly supervised sessions to reinforce compliance
o the intervention in an attempt to reach the effectiveness
emonstrated in clinical trials. Perhaps these additional costs
ould be counterbalanced with increased effectiveness, but we
pted to consider a conservative strategy in light of current
vidence. Assuming that including different professionals and
ctivities in every program is proportional to increasing costs of
he intervention, reducing the number of sessions in a facility
enter is a valuable attempt to reduce treatment costs and in-
rease cost-effectiveness ratio.
In the real world exercise therapy is not considered the core
f the standard care for HF patients. Commonly HF patients are
Fig. 6 – Acceptability curve with a willingness-to-pay of
Int$27,500/quality-adjusted life year.
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S106 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) S 1 0 0 – S 1 0 7aged and have other diseases (e.g., osteoarticular limitations)
that restrict their mobility; plus, successful exercise therapy
demands motivation and both family and patient engagement
time. In today’s health care system model, which is based in
hospital procedures, there are few examples of rehabilitation
centers to promote significant changes in patients’ habits and
minimize usual risk factors associated with cardiovascular dis-
eases, such as lack of exercise, tobacco use, inappropriate food
ingestion, and depression. Despite all these points, there is ev-
idence—including that produced in our study—that committed
patients with cardiac disease who have access to facilities with
trained professionals and appropriate equipment could benefit
from exercise therapy with reasonable cost-effectiveness ratio
[37]. Common to other interventions that also rely on human
behavior, long-term adherence to exercise in patients with HF
remains a challenge and requires additional research to deter-
mine strategies aimed at improving compliance, which might
be associated with increased effectiveness. Areas of needed re-
search include identifying the subgroups of patients who bene-
fit the most from this intervention, as well as the determining
the optimal intensity, duration, and frequency of exercise
needed to maximize clinical benefits.
Some limitations in our modeling should be mentioned.
First, we established a constant effectiveness. In the real world
a considerable number of patients oscillate their attendance in
rehabilitation programs. Another limitation is that true cost of
HF treatment could be higher than assumed costs, although we
used primary data from a cohort of HF patients, with values
updated to 2008. As we assumed a third-party payer (i.e., gov-
ernment) perspective, we did not considered patient or family
displacement cost in regard to the rehabilitation facility; indi-
rect cost associated with productivity losses were also not in-
cluded, although HF in Brazil is a retirement cause insured by
the PHS. The main caveat regarding the results of our study is
the broad variance in exercise effectiveness, even though in
two-way sensitivity analysis we found that every scenario with
effectiveness greater than 5% (considering mortality reduction)
the exercise intervention brought benefits to HF patients.
Exercise therapy seems to be safe and should be considered
in stable HF patients as part of treatment regardless of individ-
ual beliefs. Although effectiveness of exercise therapy in HF
patients seems to be lower than initially expected, its cost-ef-
fectiveness ratio remains acceptable for health policy decision
makers to incorporate this intervention in the care of patients
with HF.
Source of financial support: Dr. Rohde andDr. Polanczyk received
research sponsorship from Conselho Nacional de Desenvolvimento
Científico eTecnológico, Brazil. This studywas supported by the Bra-
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